Boston Scientific (BSX) is currently focused on advancing its presence in five categories of its endoscopy segment: pancreaticobiliary disease, gastrointestinal (or GI) cancer, gastrointestinal bleeding, infection prevention, and pulmonary diseases.
The company has estimated the consolidated addressable market opportunity in pancreaticobiliary disease to be $1.4 billion in 2018 and $1.7 billion by 2021. It has also estimated the consolidated addressable market opportunity in its GI cancer segment to be $1.4 billion in 2018 and $1.7 billion by 2021. In the GI bleeding segment, it has hemostasis devices, closure devices, and an upper GI scope, together targeting a market opportunity worth $600 million in 2018. The company expects the GI bleeding market to grow to $675 million by 2021.
In 2018, the company is targeting a market opportunity worth $425 million in the infection prevention segment. By 2021, with its compliance kits, single-use devices, and investigational duodenoscope products, the company is expected to target $625 million worth of opportunity. Finally, it’s targeting an opportunity worth $125 million with its endoscopy devices in the pulmonary disease segment. That opportunity is estimated to increase to $575 million by 2021.
Market growth strategy
While Boston Scientific’s endoscopy business was targeting a market worth $3 billion in 2015, its entry into new segments such as endoluminal surgery, pathology, and infection prevention, either through organic or inorganic growth initiatives, has helped boost the addressable market size to $5 billion in 2018.
The company is focused on investing in hemostasis, core GI procedures, pancreaticobiliary, and endoscopic ultrasound to further strengthen its position in the core areas of the endoscopy segment. It expects the addition of therapeutic imaging products and services to expand its addressable market size to $7 billion by 2021.
In the next part of this series, we’ll see how Boston Scientific is transforming its standard of care in pancreaticobiliary disease.